公开(公告)号：US11040969B2

公开(公告)日：2021-06-22

申请号：US16514413

申请日：2019-07-17

申请人： BENEVOLENTAI CAMBRIDGE LIMITED

发明人： Edward Savory ,  Michael Higginbottom ,  Kathryn Oliver ,  Viet-Anh Anne Horgan

IPC分类号： C07D471/04 ,  A61K31/437

摘要： The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.

公开(公告)号：US10988473B2

公开(公告)日：2021-04-27

申请号：US16344608

申请日：2017-10-25

申请人： BENEVOLENTAI CAMBRIDGE LIMITED

发明人： Viet-Anh Anne Horgan ,  Olof Haglund ,  Lee Patient ,  Edward Savory ,  Michael Higginbottom ,  Michael Ashwood

IPC分类号： C07D471/04

摘要： The invention relates to an improved process for the synthesis of (3S, 4S)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3H-imidazo[4,5-c]pyridine-5(4H)-carboxylate, and pharmaceutically acceptable salts thereof, such as the methanesulphonic acid salt.

公开(公告)号：US10369139B2

公开(公告)日：2019-08-06

申请号：US15567549

申请日：2016-04-22

申请人： BENEVOLENTAI CAMBRIDGE LIMITED

发明人： Edward Savory

IPC分类号： C07D471/04 ,  A61K31/437 ,  C07D307/20 ,  C07D407/14 ,  C30B29/10

摘要： A specific crystalline mesylate salt form of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate, and the use of the same in medicine. (Formula (I)).

公开(公告)号：US10399973B2

公开(公告)日：2019-09-03

申请号：US15858407

申请日：2017-12-29

申请人： BENEVOLENTAI CAMBRIDGE LIMITED

发明人： Edward Savory ,  Michael Higginbottom ,  Kathryn Oliver ,  Viet-Anh Anne Horgan

IPC分类号： A61K31/437 ,  C07D471/04

摘要： The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.

公开(公告)号：US10316034B2

公开(公告)日：2019-06-11

申请号：US15567536

申请日：2016-04-22

申请人： BENEVOLENTAI CAMBRIDGE LIMITED

发明人： Edward Savory ,  Michael Higginbottom

IPC分类号： C07D471/04 ,  A61P27/02 ,  A61P17/06 ,  A61P37/02 ,  A61P9/10 ,  A61P25/28 ,  A61P31/00 ,  A61P37/08 ,  A61P7/12 ,  A61P9/04 ,  A61P25/08 ,  A61P25/16 ,  A61P29/00 ,  A61P17/04

摘要： The mesylate and sulphate salts of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate, and hydrates thereof, and their use in medicine.